TICKERNERD
Menu
KURAKURAHealthcare · Biotechnology

KURA Stock Forecast: Kura Oncology, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$11
−1.56% on the day

The 15 Wall Street analysts covering Kura Oncology, Inc. hold a median 12-month price target of $28 — +145.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.0B
Ticker Nerd rank
79 / 100
Median analyst target
$28
Analysts covering
15
Revenue$20.9M+36.5% y/y
Operating income−$73.0M
Net income−$68.3M
Free cash flow−$63.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.4%
1M
+14.7%
YTD
+9.6%
1Y
+29.1%
From 52W high
−16.2%
From 52W low
+53.9%
$7
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KURA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kura Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Momentum
85
Revisions
84
Value
74
Volatility
68
Quality
57
Size
45
Issuance
34
Growth
21

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (21): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26KURAHigh $76Median $28Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $15Median $28High $76

The green dot is the last close — the median target sits +145.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026CitizensReiteratesMarket Outperform$24
13 Aug 2026WedbushMaintainsOutperform—
13 Aug 2026WedbushMaintainsOutperform$36 → $38
28 July 2026WedbushReiteratesOutperform$36
28 July 2026WedbushReiteratesOutperform—
15 June 2026CitizensReiteratesMarket Outperform$24
15 June 2026CitizensReiteratesMarket Outperform—
14 Apr 2026Lake StreetInitiatesBuy—
24 Mar 2026MizuhoMaintainsOutperform—
13 Mar 2026UBSMaintainsBuy—
6 Mar 2026WedbushMaintainsOutperform—
13 Jan 2026HC Wainwright & Co.ReiteratesBuy—
13 Jan 2026Leerink PartnersMaintainsOutperform—
24 Nov 2025BarclaysMaintainsOverweight—
14 Nov 2025UBSMaintainsBuy—
14 Nov 2025WedbushMaintainsOutperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025JMP SecuritiesReiteratesMarket Outperform—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
4 Sept 2025GuggenheimInitiatesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KURA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KURA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Kura Oncology, Inc. returned +29.1% against +17.5% for the S&P 500, dividends included.

KURA vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Oct 25Jan 26Apr 26Jul 26KURAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Kura Oncology, Inc. (KURA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.6×

Cheaper than 88% of US stocks

Price / sales
13.1×

Cheaper than 12% of US stocks

Price / book
20.9×

Cheaper than 4% of US stocks

EV / EBITDA
−1.6×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
36.5%

Higher than 81% of US stocks

Earnings growth (YoY)
36.5%

Higher than 69% of US stocks

Gross margin
98.8%

Higher than 99% of US stocks

Operating margin
−349.8%

Higher than 9% of US stocks

Net margin
99.9%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−167.7%

Higher than 9% of US stocks

Return on assets
−31.3%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kura Oncology, Inc. (KURA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kura Oncology, Inc. has a market value of $1.0B and an enterprise value of $518.7M.

  • Revenue in the twelve months to 30 June 2026: $77.2M. The latest quarter grew 36.5% year on year.

  • Net income over the same four quarters: −$296.8M, a −384.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.37.

  • Free cash flow in the twelve months to 30 June 2026: −$117.4M.

  • Shares outstanding: 89.0M.

  • Trailing P/E: −3.6×; forward P/E: −5.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kura Oncology, Inc. employs 260 people — $297K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

KURA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KURAKura Oncology, Inc.$1.0B
79
ABUSArbutus Biopharma Corp.$1.0B
92
JANXJanux Therapeutics, Inc.$1.0B
70
MLTXMoonLake Immunotherapeutics$1.0B
15
ATTOAttovia Therapeutics, Inc.$1.0B
0
SVRASavara, Inc.$1.0B
35
FTHFaeth Therapeutics, Inc.$965.2M
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kura Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KURA news & analysis

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

GlobeNewsWire · 9 Sept 2026positive

Kura Oncology launched Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. The launch is backed by $50 million in financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly, and others, and is designed to advance the lead candidate KO-7246 through initial clinical proof of concept.

Why it matters — A KURA watcher would care because Kura retains a substantial ownership stake in Caspian (approximately half of the company on a fully diluted basis) while the separately financed subsidiary dedicates capital and leadership to its diabetes program, allowing Kura to remain focused on oncology and potentially benefit from a new therapeutic avenue without diverting its core resources.

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

GlobeNewsWire · 8 Sept 2026neutral

Kura Oncology announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Fulk brings experience as a public company CFO with background in biopharmaceutical finance across commercial operations, R&D portfolio management, investor relations, and capital allocation.

Why it matters — KURA watchers would follow the appointment of a seasoned CFO with strong biopharmaceutical finance expertise, which brings leadership experience to the company's finance function.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

On September 1, 2026, Kura Oncology's Compensation Committee granted inducement awards of nonstatutory stock options to purchase 48,450 shares of common stock to four new employees under the Company's 2023 Inducement Option Plan. The grants were made and disclosed under Nasdaq Listing Rule 5635(c)(4).

Why it matters — KURA watchers may track these inducement grants as an indicator of new hires joining the company through equity-based incentives.

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

Zacks Investment Research · 1 Sept 2026positive

Kura Oncology's stock rose 37.6% over the past month, according to Zacks Investment Research. The gain is attributed to rising Komzifti sales, promising acute myeloid leukemia data, and pipeline catalysts that are boosting investor confidence.

Why it matters — KURA watchers would note the stock's recent momentum reflects commercial progress for Komzifti and favorable clinical data from the company's AML pipeline.

Kura Oncology to Participate in Three Investor Conferences in September

GlobeNewsWire · 1 Sept 2026neutral

Kura Oncology announced that its management will present at the Wells Fargo Healthcare Conference on September 8, 2026, as part of its participation in three investor conferences during September.

Why it matters — Investor conference presentations give KURA's management a platform to update the investment community on the company's progress in developing precision medicines for cancer.

FAQ

Frequently asked questions about KURA stock

What is the KURA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Kura Oncology, Inc. have a median 12-month price target of $28, with estimates ranging from $15 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KURA stock a buy right now?

Of the 15 analysts covering Kura Oncology, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kura Oncology, Inc. 79 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KURA?

As at 12 Sept 2026, Kura Oncology, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will KURA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +145.8% from the last close, and Ticker Nerd's factor model ranks Kura Oncology, Inc. 79 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KURA stock forecast for 2030?

No analyst covering Kura Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $76 over the next 12 months.

How has KURA stock performed over the past year?

Kura Oncology, Inc. returned +29.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kura Oncology, Inc. do?

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer.

What is the latest news on KURA?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes". Kura Oncology launched Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. The launch is backed by $50 million in financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly, and others, and is designed to advance the lead candidate KO-7246 through initial clinical proof of concept.

Company

About Kura Oncology, Inc.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected solid tumors. Its pipeline includes small-molecule drug candidates such as ziftomenib, tipifarnib, and KO-2806, which are being evaluated in clinical development for genetically defined patient populations. The company’s work combines drug discovery, biomarker-driven research, and clinical testing to support targeted treatment approaches in oncology. Based in San Diego, California, Kura Oncology operates as a focused biotechnology company within the broader cancer therapeutics market, contributing to the development of specialized therapies for patients with high unmet medical need.

CEO Dr. Troy Edward Wilson J.D., Ph.D. · 260 employees · United States · https://kuraoncology.com